Filing Flows › Guardant Health (GH) › Q2 2026
Guardant Health (GH) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 30, 2026
Guardant Health (GH) reported revenue of $335M for the second quarter 2026 (Q2 2026), +44% from a year earlier and +11% from the quarter before. Operating margin was -38.5%, net loss $120M (35.9% of revenue).
Guardant Health, Q2 2026: revenue $335M (+44% year over year), operating margin -38.5%, net loss $120M, operating cash flow −$57.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $335M | +11% | +44% |
| Operating profit | −$129M | — | — |
| Net earnings | −$120M | — | — |
| Operating cash flow | −$57.8M | — | — |
What changed
Revenue was $335.0M in Q2 2026, up 44% year over year and up 11% from the previous quarter. Oncology was the largest line at 65% of revenue. Oncology added $60.4M year over year (up 38%), 59% of the total change. Licensing and other declined 20%.
Operating costs exceeded revenue by $129.1M, an operating margin of -38.5%. Total costs grew 37% against revenue growth of 44%. The fastest-growing cost line was Sales & marketing (+59%). The quarter ended with a net loss of $120.1M, wider than the previous quarter's $112.1M loss.
Operating cash flow was −$57.8M. Non-cash charges added back $9.6M of depreciation and amortization and $57.7M of share-based compensation. Working capital and other items used $4.9M. Capital expenditures of $11.8M exceeded it, leaving free cash flow of −$69.5M.
Questions
What was Guardant Health's revenue in the second quarter 2026?
Guardant Health (GH) reported revenue of $335M for the second quarter 2026 (Q2 2026), +44% from a year earlier and +11% from the quarter before.
Was Guardant Health profitable in the second quarter 2026?
Operating loss was $129M (-38.5% of revenue) and net loss $120M.
Source: Guardant Health 10-Q on SEC EDGAR.